In selected groups of patients with atrial fibrillation, ablation can lead to an improvement in symptoms and/or prognosis. To avoid complications, anticoagulation before, during and after ablation should be criteria-driven. There is a consensus that periprocedural oral anticoagulation (OAC) is generally recommended regardless of the thromboembolic risk. On the other hand, the longer-term continuation of OAC is controversial. The ALONE-AF study published in 2025 has provided new evidence in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism
Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon
- Pediatric Retinoblastoma
The Tumor Microenvironment and Modern Eye-Sparing Therapies
- Adherence and management in asthma and COPD
Better to listen to the pharmacist
- Focus Update 2026